Your browser doesn't support javascript.
loading
Proportion of Community-Dwelling Individuals Older Than 70 Years Eligible for Lecanemab Initiation: The Gothenburg H70 Birth Cohort Study.
Dittrich, Anna; Westman, Eric; Shams, Sara; Skillbäck, Tobias; Zetterberg, Henrik; Blennow, Kaj; Zettergren, Anna; Skoog, Ingmar; Kern, Silke.
Afiliación
  • Dittrich A; From the Neuropsychiatric Epidemiology Unit (A.D., T.S., A.Z., I.S., S.K.), Sahlgrenska Academy, University of Gothenburg; Department of Psychiatry Cognition and Old Age Psychiatry (A.D., I.S., S.K.), Sahlgrenska University Hospital, Mölndal; Division of Clinical Geriatrics (E.W.), Department of Neu
  • Westman E; From the Neuropsychiatric Epidemiology Unit (A.D., T.S., A.Z., I.S., S.K.), Sahlgrenska Academy, University of Gothenburg; Department of Psychiatry Cognition and Old Age Psychiatry (A.D., I.S., S.K.), Sahlgrenska University Hospital, Mölndal; Division of Clinical Geriatrics (E.W.), Department of Neu
  • Shams S; From the Neuropsychiatric Epidemiology Unit (A.D., T.S., A.Z., I.S., S.K.), Sahlgrenska Academy, University of Gothenburg; Department of Psychiatry Cognition and Old Age Psychiatry (A.D., I.S., S.K.), Sahlgrenska University Hospital, Mölndal; Division of Clinical Geriatrics (E.W.), Department of Neu
  • Skillbäck T; From the Neuropsychiatric Epidemiology Unit (A.D., T.S., A.Z., I.S., S.K.), Sahlgrenska Academy, University of Gothenburg; Department of Psychiatry Cognition and Old Age Psychiatry (A.D., I.S., S.K.), Sahlgrenska University Hospital, Mölndal; Division of Clinical Geriatrics (E.W.), Department of Neu
  • Zetterberg H; From the Neuropsychiatric Epidemiology Unit (A.D., T.S., A.Z., I.S., S.K.), Sahlgrenska Academy, University of Gothenburg; Department of Psychiatry Cognition and Old Age Psychiatry (A.D., I.S., S.K.), Sahlgrenska University Hospital, Mölndal; Division of Clinical Geriatrics (E.W.), Department of Neu
  • Blennow K; From the Neuropsychiatric Epidemiology Unit (A.D., T.S., A.Z., I.S., S.K.), Sahlgrenska Academy, University of Gothenburg; Department of Psychiatry Cognition and Old Age Psychiatry (A.D., I.S., S.K.), Sahlgrenska University Hospital, Mölndal; Division of Clinical Geriatrics (E.W.), Department of Neu
  • Zettergren A; From the Neuropsychiatric Epidemiology Unit (A.D., T.S., A.Z., I.S., S.K.), Sahlgrenska Academy, University of Gothenburg; Department of Psychiatry Cognition and Old Age Psychiatry (A.D., I.S., S.K.), Sahlgrenska University Hospital, Mölndal; Division of Clinical Geriatrics (E.W.), Department of Neu
  • Skoog I; From the Neuropsychiatric Epidemiology Unit (A.D., T.S., A.Z., I.S., S.K.), Sahlgrenska Academy, University of Gothenburg; Department of Psychiatry Cognition and Old Age Psychiatry (A.D., I.S., S.K.), Sahlgrenska University Hospital, Mölndal; Division of Clinical Geriatrics (E.W.), Department of Neu
  • Kern S; From the Neuropsychiatric Epidemiology Unit (A.D., T.S., A.Z., I.S., S.K.), Sahlgrenska Academy, University of Gothenburg; Department of Psychiatry Cognition and Old Age Psychiatry (A.D., I.S., S.K.), Sahlgrenska University Hospital, Mölndal; Division of Clinical Geriatrics (E.W.), Department of Neu
Neurology ; 102(9): e209402, 2024 May 14.
Article en En | MEDLINE | ID: mdl-38593394
ABSTRACT

OBJECTIVES:

To determine the prevalence of individuals with Alzheimer disease (AD) eligible for treatment with the recently FDA-approved lecanemab based on data from a population-based sample of 70-year-olds and extrapolate an estimation of individuals eligible in Europe and the United States.

METHODS:

Participants from the Gothenburg H70 Birth Cohort Study with clinical data, CSF-amyloid beta 42, and brain MRI analysis were evaluated for eligibility to receive lecanemab treatment according to FDA-approved recommendations, noting factors requiring special consideration. Results were used to extrapolate the number of eligible individuals in Europe and the United States using public demographic data.

RESULTS:

Thirty (10.3%) of 290 participants met the indication for treatment of whom 18 (6.2%) were eligible and did not present factors requiring special consideration. Our estimate that 6.2% of all 70-year-olds in the full cohort are eligible for treatment extrapolates to an approximation that around 5.9 million Europeans and 2.2 million US residents could be eligible.

DISCUSSION:

Information on proportion of individuals eligible for AD treatment with lecanemab in the general public is limited. We provide information on 70-year-olds in Sweden and extrapolate these data to Europe and the United States. This study opens for larger studies on this proportion and implementation of lecanemab treatment.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Péptidos beta-Amiloides / Enfermedad de Alzheimer / Anticuerpos Monoclonales Humanizados Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Neurology Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Péptidos beta-Amiloides / Enfermedad de Alzheimer / Anticuerpos Monoclonales Humanizados Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Neurology Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos